575 related articles for article (PubMed ID: 28454118)
1. Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.
Li B; Xu L; Tao F; Xie K; Wu Z; Li Y; Li J; Chen K; Pi C; Mendelsohn A; Larrick JW; Gu H; Fang J
Oncotarget; 2017 Jun; 8(24):39356-39366. PubMed ID: 28454118
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing.
Brandsma AM; Ten Broeke T; Nederend M; Meulenbroek LA; van Tetering G; Meyer S; Jansen JH; Beltrán Buitrago MA; Nagelkerke SQ; Németh I; Ubink R; Rouwendal G; Lohse S; Valerius T; Leusen JH; Boross P
Cancer Immunol Res; 2015 Dec; 3(12):1316-24. PubMed ID: 26407589
[TBL] [Abstract][Full Text] [Related]
4. Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG.
Brandsma AM; Bondza S; Evers M; Koutstaal R; Nederend M; Jansen JHM; Rösner T; Valerius T; Leusen JHW; Ten Broeke T
Front Immunol; 2019; 10():704. PubMed ID: 31031746
[TBL] [Abstract][Full Text] [Related]
5. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
[TBL] [Abstract][Full Text] [Related]
6. IgA EGFR antibodies mediate tumour killing in vivo.
Boross P; Lohse S; Nederend M; Jansen JH; van Tetering G; Dechant M; Peipp M; Royle L; Liew LP; Boon L; van Rooijen N; Bleeker WK; Parren PW; van de Winkel JG; Valerius T; Leusen JH
EMBO Mol Med; 2013 Aug; 5(8):1213-26. PubMed ID: 23918228
[TBL] [Abstract][Full Text] [Related]
7. An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIa
Kang TH; Lee CH; Delidakis G; Jung J; Richard-Le Goff O; Lee J; Kim JE; Charab W; Bruhns P; Georgiou G
Front Immunol; 2019; 10():562. PubMed ID: 30984171
[TBL] [Abstract][Full Text] [Related]
8. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
Braster R; O'Toole T; van Egmond M
Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
[TBL] [Abstract][Full Text] [Related]
9. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.
Snyder KM; Hullsiek R; Mishra HK; Mendez DC; Li Y; Rogich A; Kaufman DS; Wu J; Walcheck B
Front Immunol; 2018; 9():2873. PubMed ID: 30574146
[TBL] [Abstract][Full Text] [Related]
10. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies.
Huls G; Heijnen IA; Cuomo E; van der Linden J; Boel E; van de Winkel JG; Logtenberg T
Cancer Res; 1999 Nov; 59(22):5778-84. PubMed ID: 10582699
[TBL] [Abstract][Full Text] [Related]
11. Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy.
Stockmeyer B; Dechant M; van Egmond M; Tutt AL; Sundarapandiyan K; Graziano RF; Repp R; Kalden JR; Gramatzki M; Glennie MJ; van de Winkel JG; Valerius T
J Immunol; 2000 Nov; 165(10):5954-61. PubMed ID: 11067958
[TBL] [Abstract][Full Text] [Related]
12. Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors.
Bruckheimer EM; Fazenbaker CA; Gallagher S; Mulgrew K; Fuhrmann S; Coffman KT; Walsh W; Ready S; Cook K; Damschroder M; Kinch M; Kiener PA; Woods R; Gao C; Dall'Acqua W; Wu H; Coats S
Neoplasia; 2009 Jun; 11(6):509-17, 2 p following 517. PubMed ID: 19484140
[TBL] [Abstract][Full Text] [Related]
13. Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin.
Srivastava S; Pelloso D; Feng H; Voiles L; Lewis D; Haskova Z; Whitacre M; Trulli S; Chen YJ; Toso J; Jonak ZL; Chang HC; Robertson MJ
Cancer Immunol Immunother; 2013 Jun; 62(6):1073-82. PubMed ID: 23604103
[TBL] [Abstract][Full Text] [Related]
14. Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
Chen Y; You F; Jiang L; Li J; Zhu X; Bao Y; Sun X; Tang X; Meng H; An G; Zhang B; Yang L
Oncotarget; 2017 Jun; 8(23):37128-37139. PubMed ID: 28415754
[TBL] [Abstract][Full Text] [Related]
15. Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicity.
Li G; Zhang L; Chen E; Wang J; Jiang X; Chen JH; Wickman G; Amundson K; Bergqvist S; Zobel J; Buckman D; Baxi SM; Bender SL; Casperson GF; Hu-Lowe DD
Cancer Res; 2010 Dec; 70(24):10243-54. PubMed ID: 21159645
[TBL] [Abstract][Full Text] [Related]
16. Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity.
Heemskerk N; Gruijs M; Temming AR; Heineke MH; Gout DY; Hellingman T; Tuk CW; Winter PJ; Lissenberg-Thunnissen S; Bentlage AE; de Donatis M; Bögels M; Rösner T; Valerius T; Bakema JE; Vidarsson G; van Egmond M
J Clin Invest; 2021 Mar; 131(6):. PubMed ID: 33561014
[TBL] [Abstract][Full Text] [Related]
17. FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy.
Valerius T; Stockmeyer B; van Spriel AB; Graziano RF; van den Herik-Oudijk IE; Repp R; Deo YM; Lund J; Kalden JR; Gramatzki M; van de Winkel JG
Blood; 1997 Dec; 90(11):4485-92. PubMed ID: 9373259
[TBL] [Abstract][Full Text] [Related]
18. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
[TBL] [Abstract][Full Text] [Related]
19. Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies.
Horton HM; Bernett MJ; Peipp M; Pong E; Karki S; Chu SY; Richards JO; Chen H; Repp R; Desjarlais JR; Zhukovsky EA
Blood; 2010 Oct; 116(16):3004-12. PubMed ID: 20616215
[TBL] [Abstract][Full Text] [Related]
20. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
